| Primary |
| Breast Cancer |
46.1% |
| Breast Cancer Metastatic |
19.8% |
| Drug Use For Unknown Indication |
15.4% |
| Product Used For Unknown Indication |
7.7% |
| Gastric Cancer |
2.3% |
| Breast Cancer Female |
1.8% |
| Metastatic Gastric Cancer |
1.0% |
| Hypertension |
0.8% |
| Premedication |
0.7% |
| Her-2 Positive Breast Cancer |
0.7% |
| Breast Cancer Recurrent |
0.5% |
| Pain |
0.5% |
| Neoplasm Malignant |
0.4% |
| Transitional Cell Carcinoma |
0.4% |
| Prophylaxis |
0.4% |
| Metastases To Bone |
0.3% |
| Metastases To Liver |
0.3% |
| Nausea |
0.3% |
| Osteosarcoma Metastatic |
0.3% |
| Metastatic Neoplasm |
0.3% |
|
| Death |
37.1% |
| Disease Progression |
14.3% |
| Ejection Fraction Decreased |
5.1% |
| Metastases To Central Nervous System |
4.5% |
| Myocarditis |
4.1% |
| Vomiting |
3.8% |
| Malignant Neoplasm Progression |
3.5% |
| Pyrexia |
2.8% |
| Pulmonary Embolism |
2.7% |
| Myocardial Infarction |
2.6% |
| Cardiac Disorder |
2.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.4% |
| Thrombocytopenia |
2.4% |
| Dyspnoea |
2.1% |
| Pericardial Effusion |
1.9% |
| Tachycardia |
1.7% |
| Febrile Neutropenia |
1.7% |
| Neutropenia |
1.7% |
| Rash |
1.7% |
| White Blood Cell Count Decreased |
1.6% |
|
| Secondary |
| Breast Cancer |
40.5% |
| Product Used For Unknown Indication |
22.7% |
| Breast Cancer Metastatic |
18.5% |
| Drug Use For Unknown Indication |
4.1% |
| Gastric Cancer |
1.8% |
| Breast Cancer Female |
1.8% |
| Breast Cancer Recurrent |
1.4% |
| Metastatic Gastric Cancer |
1.0% |
| Her-2 Positive Breast Cancer |
1.0% |
| Prophylaxis |
0.9% |
| Premedication |
0.8% |
| Metastases To Bone |
0.8% |
| Chemotherapy |
0.7% |
| Metastases To Liver |
0.7% |
| Hypertension |
0.7% |
| Pain |
0.7% |
| Nausea |
0.6% |
| Neoplasm Malignant |
0.5% |
| Metastases To Lung |
0.5% |
| Bone Neoplasm Malignant |
0.5% |
|
| Death |
15.8% |
| Disease Progression |
12.4% |
| Vomiting |
11.3% |
| Vulvovaginal Dryness |
6.0% |
| Pyrexia |
5.3% |
| Rash |
5.0% |
| White Blood Cell Count Decreased |
4.8% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
4.7% |
| Neutropenia |
3.8% |
| Pleural Effusion |
3.5% |
| Ejection Fraction Decreased |
3.3% |
| Myocarditis |
3.3% |
| Pain |
3.3% |
| Weight Decreased |
3.1% |
| Diarrhoea |
3.0% |
| Pulmonary Embolism |
2.8% |
| Metastases To Liver |
2.4% |
| Weight Increased |
2.3% |
| Thrombocytopenia |
2.1% |
| Febrile Neutropenia |
2.0% |
|
| Concomitant |
| Breast Cancer |
34.0% |
| Metastases To Bone |
15.8% |
| Breast Cancer Metastatic |
12.2% |
| Pain |
6.3% |
| Product Used For Unknown Indication |
5.2% |
| Depression |
4.9% |
| Chemotherapy |
2.4% |
| Prophylaxis |
1.7% |
| Metastasis |
1.7% |
| Nausea |
1.6% |
| Drug Use For Unknown Indication |
1.6% |
| Breast Cancer Female |
1.6% |
| Osteoporosis |
1.5% |
| Hypertension |
1.5% |
| Breast Cancer Recurrent |
1.5% |
| Premedication |
1.4% |
| Neoplasm Malignant |
1.4% |
| Sleep Disorder |
1.4% |
| Muscle Spasms |
1.3% |
| Hypercalcaemia |
1.1% |
|
| Vomiting |
14.4% |
| Weight Decreased |
9.6% |
| Tooth Extraction |
9.2% |
| Diarrhoea |
8.1% |
| Osteonecrosis |
6.1% |
| Vision Blurred |
5.1% |
| Rash |
5.0% |
| White Blood Cell Count Decreased |
4.4% |
| Toothache |
3.9% |
| Weight Increased |
3.9% |
| Wheezing |
3.9% |
| Death |
3.5% |
| Metastases To Lung |
3.3% |
| Pyrexia |
3.3% |
| Osteonecrosis Of Jaw |
3.1% |
| Trismus |
2.9% |
| White Blood Cell Count Increased |
2.8% |
| Wound Debridement |
2.6% |
| Nausea |
2.4% |
| Stomatitis |
2.4% |
|
| Interacting |
| Breast Cancer Metastatic |
41.7% |
| Breast Cancer |
36.1% |
| Drug Use For Unknown Indication |
8.3% |
| Hiv Infection |
5.6% |
| Product Used For Unknown Indication |
2.8% |
| Prophylaxis Of Nausea And Vomiting |
2.8% |
| Pyelonephritis |
2.8% |
|
| Drug Interaction |
26.7% |
| Musculoskeletal Stiffness |
20.0% |
| Bradycardia |
13.3% |
| Pancreatitis |
13.3% |
| Infusion Site Extravasation |
6.7% |
| Mucosal Inflammation |
6.7% |
| Red Blood Cell Count Decreased |
6.7% |
| Stomatitis |
6.7% |
|
